118 related articles for article (PubMed ID: 29852247)
1. Nuclear accumulation of SHIP1 mutants derived from AML patients leads to increased proliferation of leukemic cells.
Nalaskowski MM; Ehm P; Rehbach C; Nelson N; Täger M; Modest K; Jücker M
Cell Signal; 2018 Sep; 49():87-94. PubMed ID: 29852247
[TBL] [Abstract][Full Text] [Related]
2. SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model.
Täger M; Horn S; Latuske E; Ehm P; Schaks M; Nalaskowski M; Fehse B; Fiedler W; Stocking C; Wellbrock J; Jücker M
Gene Ther; 2017 Nov; 24(11):749-753. PubMed ID: 29143813
[TBL] [Abstract][Full Text] [Related]
3. The inositol 5-phosphatase SHIP1 is a nucleo-cytoplasmic shuttling protein and enzymatically active in cell nuclei.
Nalaskowski MM; Metzner A; Brehm MA; Labiadh S; Brauer H; Grabinski N; Mayr GW; Jücker M
Cell Signal; 2012 Mar; 24(3):621-8. PubMed ID: 21864674
[TBL] [Abstract][Full Text] [Related]
4. Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling.
Brauer H; Strauss J; Wegner W; Müller-Tidow C; Horstmann M; Jücker M
Cell Signal; 2012 Nov; 24(11):2095-101. PubMed ID: 22820502
[TBL] [Abstract][Full Text] [Related]
5. Reduced expression and activity of patient-derived SHIP1 phosphatase domain mutants.
Ehm P; Nelson N; Giehler S; Schaks M; Bettin B; Kirchmair J; Jücker M
Cell Signal; 2023 Jan; 101():110485. PubMed ID: 36208705
[TBL] [Abstract][Full Text] [Related]
6. SHIP1 is targeted by miR-155 in acute myeloid leukemia.
Xue H; Hua LM; Guo M; Luo JM
Oncol Rep; 2014 Nov; 32(5):2253-9. PubMed ID: 25175984
[TBL] [Abstract][Full Text] [Related]
7. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).
Glück M; Dally L; Jücker M; Ehm P
Int J Biochem Cell Biol; 2022 Aug; 149():106229. PubMed ID: 35609769
[TBL] [Abstract][Full Text] [Related]
8. The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies.
Ehm P; Nalaskowski MM; Wundenberg T; Jücker M
Nucleus; 2015; 6(2):154-64. PubMed ID: 25723258
[TBL] [Abstract][Full Text] [Related]
9. Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D.
Metzner A; Precht C; Fehse B; Fiedler W; Stocking C; Günther A; Mayr GW; Jücker M
Gene Ther; 2009 Apr; 16(4):570-3. PubMed ID: 19148132
[TBL] [Abstract][Full Text] [Related]
10. Jarid1b promotes epidermal differentiation by mediating the repression of Ship1 and activation of the AKT/Ovol1 pathway.
Sun X; Li Z; Niu Y; Zhao L; Huang Y; Li Q; Zhang S; Chen T; Fu T; Yang T; An X; Jiang Y; Zhang J
Cell Prolif; 2019 Sep; 52(5):e12638. PubMed ID: 31152465
[TBL] [Abstract][Full Text] [Related]
11. Differential Lyn-dependence of the SHIP1-deficient mast cell phenotype.
Nunes de Miranda SM; Wilhelm T; Huber M; Zorn CN
Cell Commun Signal; 2016 May; 14(1):12. PubMed ID: 27206658
[TBL] [Abstract][Full Text] [Related]
12. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.
Nepstad I; Hatfield KJ; Aasebø E; Hernandez-Valladares M; Brenner AK; Bartaula-Brevik S; Berven F; Selheim F; Skavland J; Gjertsen BT; Reikvam H; Bruserud Ø
Expert Opin Ther Targets; 2018 Jul; 22(7):639-653. PubMed ID: 29889583
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the FLVR motif of SHIP1 and its importance for the protein stability of SH2 containing signaling proteins.
Ehm PAH; Lange F; Hentschel C; Jepsen A; Glück M; Nelson N; Bettin B; de Bruyn Kops C; Kirchmair J; Nalaskowski M; Jücker M
Cell Signal; 2019 Nov; 63():109380. PubMed ID: 31377397
[TBL] [Abstract][Full Text] [Related]
14. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
[TBL] [Abstract][Full Text] [Related]
15. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms controlling membrane recruitment and activation of the autoinhibited SHIP1 inositol 5-phosphatase.
Waddell GL; Drew EE; Rupp HP; Hansen SD
J Biol Chem; 2023 Aug; 299(8):105022. PubMed ID: 37423304
[TBL] [Abstract][Full Text] [Related]
17. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis.
Kodigepalli KM; Bonifati S; Tirumuru N; Wu L
Cell Cycle; 2018; 17(9):1124-1137. PubMed ID: 29911928
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Lemm EA; Valle-Argos B; Smith LD; Richter J; Gebreselassie Y; Carter MJ; Karolova J; Svaton M; Helman K; Weston-Bell NJ; Karydis L; Williamson CT; Lenz G; Pettigrew J; Harwig C; Stevenson FK; Cragg M; Forconi F; Steele AJ; Cross J; Mackenzie L; Klener P; Packham G
Clin Cancer Res; 2020 Apr; 26(7):1700-1711. PubMed ID: 31831562
[TBL] [Abstract][Full Text] [Related]
19. Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia.
Ecker V; Stumpf M; Brandmeier L; Neumayer T; Pfeuffer L; Engleitner T; Ringshausen I; Nelson N; Jücker M; Wanninger S; Zenz T; Wendtner C; Manske K; Steiger K; Rad R; Müschen M; Ruland J; Buchner M
Nat Commun; 2021 Jun; 12(1):3526. PubMed ID: 34112805
[TBL] [Abstract][Full Text] [Related]
20. SHIP1 inhibits cell growth, migration, and invasion in non‑small cell lung cancer through the PI3K/AKT pathway.
Fu Q; Huang Y; Ge C; Li Z; Tian H; Li Q; Li H; Li R; Tao X; Xue Y; Wang Y; Yang G; Fang W; Song X
Oncol Rep; 2019 Apr; 41(4):2337-2350. PubMed ID: 30720128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
